# Development of second-generation probiotics as radiation mitigators

> **NIH NIH N01** · CHROMOLOGIC, LLC · 2024 · $43,965

## Abstract

The University of Pittsburgh and the University of Wisconsin have developed a Lactobacillus reuteri-based cytokine delivery platform (LRC-DP) to mitigate acute gastrointestinal radiation syndrome (GI-ARS) and has licensed this technology to ChromoLogic. ChromoLogic has developed a LRC-DP construct that produces the cytokines IL-22 or IFN-β and plans to test efficacy in animal models of GI-ARS.

## Key facts

- **NIH application ID:** 11088007
- **Project number:** 75N93021C00008-P00011-9999-1
- **Recipient organization:** CHROMOLOGIC, LLC
- **Principal Investigator:** CLAUDE ROGERS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $43,965
- **Award type:** —
- **Project period:** 2021-03-16 → 2025-03-15

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11088007

## Citation

> US National Institutes of Health, RePORTER application 11088007, Development of second-generation probiotics as radiation mitigators (75N93021C00008-P00011-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/11088007. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*